If you cannot see this email please follow this link.
Newsletter Regulatory Affairs
Your monthly regulatory affairs update
{Anrede},

Welcome to the July 2023 issue of the regulatory affairs newsletter.

Today you will receive an overview of regulatory issues of the last few weeks and a summary of the Biosimilars event, focussing on the new aut idem rules in Germany.
Editorial
News from the ICH
News from HMA
News from EMA
Veterinary news
Monthly reports
The online conference "Biosimilars 2023 – the Aut idem rules" took place on 5 July 2023.

Author: Dr Henriette Wolf-Klein, FORUM Institut für Management GmbH

The starting point of the event was the Federal Joint Committee (G-BA) decision of 15 June 2023, which regulated the interchangeability of medically prescribed preparations of finished medicinal products with biotechnologically produced active ingredients in pharmacies and thus gave the starting signal for biosimilar aut idem. ... more
News from the ICH
The ICH E6(R3) draft Guideline on "Good Clinical Practice" reached Step 2b of the ICH Process in May 2023 and subsequently entered the consultation period.
Details


News from HMA
EMA and the Heads of Medicines Agencies (HMA) are running a pilot project to enable clinical-oncology scientists to participate in medicine regulation. The pilot focuses on scientific advice and marketing authorisation assessments for human medicines.
Details


PharmaFORUM Webcast International - More information >>


News from EMA
The Guideline on clinical investigation of medicinal products in the treatment or prevention of diabetes mellitus will come into effect 1 January 2024.
Details


EMA and EU Commission have published the "Guidance on Parallel EMA/HTA body (HTAb) Scientific Advice for the Interim Period".
Details


A webcast series consisting of the parts EU-HTA legislation, EU-HTA dossier compilation and national EU-HTA preparation in France, Italy, Spain and the UK will also cover this Guidance.
Details


EMA publishes a report on "real-world evidence framework to support EU regulatory decision-making".
Details


Veterinary news
The VICH GL18(R2) impurities: residual solvents in new veterinary medicinal products, active substances and excipients will come into effect in April 2024.
Details


PharmaFORUM Webcast Biologics - More information >>


Monthly reports
PRAC:
Details


CHMP:
Details


CMDh:
Details


CVMP:
Details

Kind regards,

Dr Rebekka Bitsch
Your contact for
Regulatory Affairs (Human)
+49 6221 500-565
Dr C. Michaela Gottwald
Your contact for
Regulatory Affairs (Veterinary)
+49 6221 500-610
Dr Birgit Wessels
Your contact for
Quality, Safety, CMC
+49 6221 500-652


TO UNSUBSCRIBE:
If you do not want to receive this information in future, you can unsubscribe here!
FORUM · Institut für Management GmbH · Vangerowstr. 18 · 69115 Heidelberg · Germany
Fon +49 6221 500-500 · Fax +49 6221 500-555 · service@forum-institut.de · www.forum-institut.com
Copyright 2023 FORUM · Institut für Management GmbH
Imprint, privacy policy, terms and conditions